-+ 0.00%
-+ 0.00%
-+ 0.00%

Klotho Neurosciences Regains Nasdaq Compliance, Avoids Delisting Over Stock Price and Equity Rules

Benzinga·07/16/2025 10:04:54
Listen to the news

Klotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that it had received a notification letter from The NASDAQ Stock Market LLC confirming that the Company has regained compliance with the minimum $1.00 bid price under NASDAQ Listing Rule 5550(a)(2), and the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1).

 

The Company is now in full compliance with all NASDAQ continued listing requirements and will remain listed and traded on the NASDAQ Stock Market.